Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Solar ETF (TAN) vs Viatris Inc (VTRS) Price & Performance

Invesco Solar ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Invesco Solar ETF vs Viatris Inc — how do they compare? Invesco Solar ETF trades at $47.83, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while Invesco Solar ETF pays none, and Viatris Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.

TANVTRS
Sector
Sector/ThematicHealth
52-Week High
$73.95$17.86
52-Week Low
$41.78$9.49
Market Cap
$19.09B
Enterprise Value
$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Solar ETF

TAN trades at $49.13, up 2.27% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The solar ETF faces mixed sentiment; recent news highlights policy tailwinds from U.S. tariffs but also sector risks like market saturation and high volatility. Financial ratios are unavailable, limiting fundamental clarity, while institutional activity includes Bank of America increasing its stake in Q1 2026.

Outlook is cautious: geopolitical shifts and AI-driven energy demand offer growth potential, but headwinds include price deflation, regulatory uncertainty, and underperformance versus broad markets. Risks center on expense ratios, drawdowns, and competition, requiring careful evaluation for volatility-tolerant investors.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco Solar ETF

TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.

Read more on TAN

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS